ArticleBritish journal of cancer2001
Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice.
Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 102 citations in OpenAlex.
- Anemia in cervical cancer patients: implications for iron supplementation therapy.Medical oncology (Northwood, London, England) · 2005Trial
- A Molecular Perspective on HIF-1α and Angiogenic Stimulator Networks and Their Role in Solid Tumors: An Update.International journal of molecular sciences · 2024Review
- Serum erythropoietin levels, breast cancer and breast cancer-initiating cells.Breast cancer research : BCR · 2019Article
- Erythropoietin Receptor Antagonist Suppressed Ectopic Hemoglobin Synthesis in Xenografts of HeLa Cells to Promote Their Destruction.PloS one · 2015Article
- Expression of the erythropoietin receptor by germline-derived cells - further support for a potential developmental link between the germline and hematopoiesis.Journal of ovarian research · 2014Article
- Induction of erythropoietin increases the cell proliferation rate in a hypoxia-inducible factor-1-dependent and -independent manner in renal cell carcinoma cell lines.Oncology letters · 2013Article
- Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation.British journal of cancer · 2012Article
- Clinical significance of erythropoietin receptor expression in oral squamous cell carcinoma.BMC cancer · 2012Article
- The effect of erythropoietin on normal and neoplastic cells.Biologics : targets & therapy · 2012Article
- Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2011Review
- Epo is involved in angiogenesis in human glioma.Journal of neuro-oncology · 2011Article
- Erythropoietin is involved in angiogenesis in human primary melanoma.International journal of experimental pathology · 2010Article
- Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents.Archives of internal medicine · 2010Review
- Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression.Translational oncology · 2010Article
- Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis.Neoplasia (New York, N.Y.) · 2008Article
- Using gene transfer to circumvent off-target effects.Gene therapy · 2008Review
- Effects of recombinant erythropoietin on breast cancer-initiating cells.Neoplasia (New York, N.Y.) · 2007Review
- Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression.PloS one · 2007Article
- Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma.Histopathology · 2007Article
- Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma.Histopathology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have recently shown that malignant tumours from the ovary and uterus expressed erythropoietin (Epo) and its receptor (EpoR), and that deprivation of Epo signal in tumour blocks induced death of malignant cells and capillary endothelial cells in vitro (Yasuda et al, submitted). These in vitro results prompted us to examine the effect of Epo-signal withdrawal on tumours in vivo. RT-PCR analysis demonstrated the expression of mRNAs for Epo and EpoR in the transplants of uterine and ovarian tumours in nude mice. Then we injected locally anti-Epo antibody or soluble form of EpoR into the transplants. At 12 h, 1, 7 or 14 days after the injection, all transplants were resected and examined macro- and microscopically. Tumour size was reduced in Epo signal-deprived transplants. Immunohistochemical examinations revealed destruction of Epo-responding malignant and capillary endothelial cells through apoptotic death. The degree of tumour regression correlated well with the dose and frequency of the injections. Control xenografts with saline injection or needle insertion showed well-developed tumour masses. This Epo response pathway will have profound implications for our understanding of the development and progression of malignant tumours and for the use of Epo-signal deprivation as an effective therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.